2 Anti-Kickback Developments Hold Lessons For Biopharma
Last year ushered in new Anti-Kickback Statute concerns for biopharma companies after Ultragenyx Pharmaceutical Inc. paid $6 million to settle U.S. Department of Justice allegations about its free genetic testing program...To view the full article, register now.
Already a subscriber? Click here to view full article